Taking ACTioN
Bringing the science of cell therapy into autoimmune disease, together
CAR T cell therapy is a proven, transformational treatment across many forms of blood cancer, and holds the potential to make similar advances within the care of patients with certain autoimmune diseases.
With industry-leading expertise, Bristol Myers Squibb is leveraging cutting-edge research capabilities across cell therapies, T-cell engagers and more, combined with a deep well of partnerships across cell therapy and immunology, to pioneer new frontiers and bring CAR T cell therapy beyond cancer and into the field of autoimmune disease.
Scientific collaboration plays a crucial role in making new discoveries and accelerating these advances to patients. That’s why BMS is convening ACTioN (Autoimmunity Cell Therapy Network), with leading academics and physicians to advance cell therapy in autoimmune diseases – together.
Advancing the science together: Introducing ACTioN
BMS has established the ACTioN Steering Committee, with key leaders in the field, to build an extended network of trusted clinical experts within the autoimmune and cell therapy communities, to accelerate these treatments from bench to clinic.
Our ACTioN Pillars are three-fold: scientific leadership, clinical leadership and ecosystem expansion. Together, we will gather insights, discuss strategies for investment and research, address challenges and chart a path forward.
“
![closing quote](/https/www.bms.com/assets/bms-ar/images/2023/quote-2.png)
”
Jonathan Leith, PhD Chair
Daniela van Eickels, MD, MPH Co-Chair
Rosanna Ricafort, MD Co-Chair